Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19

• Status: Recruiting
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effect of Andrographis Extract, Boesenbergia Extract compared to standard treatment in asymptomatic COVID patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Collaborator: Ministry of Health, Thailand
• Treatments: Andrographolide

Criteria

Inclusion Criteria:

1. Age 18- 60 years old

2. Have been diagnosed as new COVID-19 case by RT-PCR since disease onset to admission less than 7 days

3. Have asymptomatic infection assessed by the World Health Organization (WHO) disease category

4. Do not have any of following disease or conditions

1. Body weight > 90 kg or BMI > 30 kg/m2

2. Hypertension that needs antihypertensive medication

3. Diabetes

4. Cardiovascular diseases including congenital heart disease

5. Cerebrovascular diseases

6. Chronic kidney and chronic liver diseases

7. COPD or chronic lung diseases

8. Lymphocyte <1,000 cells/mm3

9. Late-stage cancer

10. Auto-immune disease (e.g., SLE, Rheumatoid arthritis, multiple sclerosis, etc.) or currently on immunosuppressive drug

11. Coagulation disorders or platelet disorders and are being treated with anticoagulants such as warfarin, clopidogrel

12. Pregnancy

5. Willing to participate with the study and sign inform consents.

(Withdrawal criteria)

1. Patients withdraw from the study

2. Have severe adverse effect that may relate to Andographolide or Boesenbergia